These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 26564592

  • 1. Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study.
    Tientcheu D, Ayers C, Das SR, McGuire DK, de Lemos JA, Khera A, Kaplan N, Victor R, Vongpatanasin W.
    J Am Coll Cardiol; 2015 Nov 17; 66(20):2159-2169. PubMed ID: 26564592
    [Abstract] [Full Text] [Related]

  • 2. Association of Cardiovascular Outcomes With Masked Hypertension Defined by Home Blood Pressure Monitoring in a Japanese General Practice Population.
    Fujiwara T, Yano Y, Hoshide S, Kanegae H, Kario K.
    JAMA Cardiol; 2018 Jul 01; 3(7):583-590. PubMed ID: 29800067
    [Abstract] [Full Text] [Related]

  • 3. White-Coat and Reverse White-Coat Effects Correlate with 24-h Pulse Pressure and Systolic Blood Pressure Variability in Children and Young Adults.
    Fujita H, Matsuoka S, Awazu M.
    Pediatr Cardiol; 2016 Feb 01; 37(2):345-52. PubMed ID: 26481222
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of olmesartan-based treatment on home and clinic blood pressure in elderly patients with masked and white coat hypertension.
    Kushiro T, Kario K, Saito I, Teramukai S, Mori Y, Okuda Y, Shimada K.
    Hypertens Res; 2015 Mar 01; 38(3):178-85. PubMed ID: 25354777
    [Abstract] [Full Text] [Related]

  • 5. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements.
    Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, Grassi G.
    Hypertension; 2013 Jul 01; 62(1):168-74. PubMed ID: 23716584
    [Abstract] [Full Text] [Related]

  • 6. Subclinical arterial and cardiac damage in white-coat and masked hypertension.
    Wojciechowska W, Stolarz-Skrzypek K, Olszanecka A, Klima Ł, Gąsowski J, Grodzicki T, Kawecka-Jaszcz K, Czarnecka D.
    Blood Press; 2016 Aug 01; 25(4):249-56. PubMed ID: 26953075
    [Abstract] [Full Text] [Related]

  • 7. Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study.
    Kushiro T, Kario K, Saito I, Teramukai S, Sato Y, Okuda Y, Shimada K.
    Hypertens Res; 2017 Jan 01; 40(1):87-95. PubMed ID: 27511054
    [Abstract] [Full Text] [Related]

  • 8. Office blood pressure is a predictor of aortic elastic properties and urinary protein excretion in subjects with white coat hypertension.
    Aznaouridis K, Vlachopoulos C, Masoura K, Pietri P, Vyssoulis G, Ioakeimidis N, Stefanadis C, Tousoulis D.
    Int J Cardiol; 2016 Jan 15; 203():98-103. PubMed ID: 26498870
    [Abstract] [Full Text] [Related]

  • 9. Adverse prognostic value of persistent office blood pressure elevation in white coat hypertension.
    Mancia G, Facchetti R, Grassi G, Bombelli M.
    Hypertension; 2015 Aug 15; 66(2):437-44. PubMed ID: 26056342
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic significance of masked and white-coat hypertension in the general population: the Finn-Home Study.
    Hänninen MR, Niiranen TJ, Puukka PJ, Johansson J, Jula AM.
    J Hypertens; 2012 Apr 15; 30(4):705-12. PubMed ID: 22278146
    [Abstract] [Full Text] [Related]

  • 14. Are metabolic risk factors and target organ damage more frequent in masked hypertension than in white coat hypertension?
    Yoon HJ, Ahn Y, Park JB, Park CG, Youn HJ, Choi DJ, Shin JH, Kim DW, Rim SJ, Bae JH, Korean Hypertension Research Network.
    Clin Exp Hypertens; 2010 Apr 15; 32(7):480-5. PubMed ID: 21029014
    [Abstract] [Full Text] [Related]

  • 15. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome.
    Stergiou GS, Asayama K, Thijs L, Kollias A, Niiranen TJ, Hozawa A, Boggia J, Johansson JK, Ohkubo T, Tsuji I, Jula AM, Imai Y, Staessen JA, International Database on HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO) Investigators.
    Hypertension; 2014 Apr 15; 63(4):675-82. PubMed ID: 24420553
    [Abstract] [Full Text] [Related]

  • 16. Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage.
    Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, Deo R, Fischer MJ, He J, Hsu CY, Huan Y, Keane MG, Kusek JW, Makos GK, Miller ER, Soliman EZ, Steigerwalt SP, Taliercio JJ, Townsend RR, Weir MR, Wright JT, Xie D, Rahman M, Chronic Renal Insufficiency Cohort Study Investigators.
    Clin J Am Soc Nephrol; 2016 Apr 07; 11(4):642-52. PubMed ID: 26912547
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Target organ complications and prognostic significance of alerting reaction: analysis from the Dallas Heart Study.
    Velasco A, Ayers C, Das SR, de Lemos JA, Khera A, Victor RG, Kaplan NM, Vongpatanasin W.
    J Hypertens; 2016 Feb 07; 34(2):226-34. PubMed ID: 26485459
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.